Delivery Order SPE2DE24DA017-SPE2D625F1DF7
- Not listed
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $1,817.64 delivery order from the Defense Logistics Agency's Medical Supply Chain on August 13, 2025, for an ACP MAX PRP (Autologous Conditioned Plasma Maximum Platelet-Rich Plasma) System with Autologous Conditioned Plasma technology. This fixed-price contract with economic price adjustment provisions is set to conclude by August 18, 2025, and represents a task order under Arthrex's larger Indefinite...
- Arthrex Inc., a Naples, Florida-based orthopedic medical technology company, received a delivery order valued at $6,058.80 from the Defense Logistics Agency's Medical Supply Chain on September 25, 2025, for the ACP MAX PRP System with ACDA. This fixed-price delivery order with economic price adjustment is scheduled for completion by September 30, 2025, and will be performed in Naples, Florida. The delivery order was awarded without a set-aside designation, reflecting Arthrex's competitive...
- Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies headquartered in Naples, Florida, was awarded a delivery order valued at $7,270.56 on September 12, 2025, for the ACP MAX PRP System with ACDA. This fixed-price delivery order with economic price adjustment falls under the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency responsible for supplying medical products to Department of Defense and Department of Veterans Affairs...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $52,879.14 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on August 4, 2025, for an ACP MAX PRP System with ACDA technology. This delivery order represents a task order under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) valued at $471 million and running through September 1, 2029. The contract carries no set-aside designation, reflecting Arthrex's...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $20,710.80 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain for the ACP MAX PRP System (OUS/EU). Awarded on September 5, 2025, with an ultimate completion date of September 10, 2025, this delivery order is issued under a larger indefinite delivery contract (IDC SPE2DE24D0020) valued at $471 million and running through September 1, 2029. The contract includes economic...
- Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies headquartered in Naples, Florida, was awarded a delivery order valued at $14,503.50 on July 11, 2025, for the ACP MAX PRP System with ACDA. This fixed-price delivery order with economic price adjustment was issued under the Defense Logistics Agency's Medical Supply Chain and carries an ultimate completion date of July 16, 2025. The award represents work to be performed in Naples, Florida, and was made without a...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, was awarded a delivery order valued at $3,029.40 on August 27, 2025, for the ACP MAX PRP System with ACDA (autologous conditioned plasma). This fixed-price delivery order with economic price adjustment is scheduled for completion by September 2, 2025, and represents performance under Arthrex's larger indefinite delivery contract with the Defense Logistics Agency's Medical Supply Chain. The order...
- Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies, was awarded a delivery order valued at $3,111.90 on August 22, 2025, under a fixed-price contract with economic price adjustment provisions. The order, identified as 4569186034 and titled "ACP MAX PRP SYSTEM (W/ ACDA)," is scheduled for completion by August 27, 2025, with performance to be executed in Naples, Florida. This delivery order was issued without a set-aside designation, reflecting...
- Arthrex Inc., a leading global provider of minimally invasive orthopedic medical technologies based in Naples, Florida, has been awarded a delivery order valued at $1,817.64 for an ACP MAX PRP System with ACDA under a Defense Logistics Agency Medical Supply Chain contract. The award, announced on August 29, 2025, is a fixed-price delivery order with economic price adjustment provisions and is set to be completed by September 4, 2025. This delivery order falls under Arthrex's larger Indefinite...
- Arthrex Inc., a leading manufacturer of minimally invasive orthopedic medical technologies based in Naples, Florida, received a fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, valued at $2,146.32. The order covers the supply of Arthrex ANGEL PRP Kits (autologous platelet-rich plasma kits) and is scheduled for completion by July 28, 2025. This delivery order was awarded without a set-aside designation, reflecting Arthrex's strong competitive...
- SPE2DE24DA017Indefinite Delivery Contract
- SPE2DE24DA017-SPE2D625F1DF7Delivery Order
Arthrex Inc., a leading orthopedic medical device manufacturer headquartered in Naples, Florida, received a delivery order valued at $1,211.76 from the Defense Logistics Agency's Medical Supply Chain on June 6, 2025. The order, designated as contract 4568471533 for an ACP MAX PRP System with ACDA (Autologous Conditioned Plasma with Advanced Concentrated Data Analysis), is structured as a fixed-price delivery order with economic price adjustment provisions and carries a completion date of June 11, 2025. The work will be performed in Naples, Florida, and no small business set-aside was applied to this award, reflecting Arthrex's competitive standing in the federal orthopedic medical device marketplace. This delivery order is issued under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency, a comprehensive $471 million vehicle running through September 1, 2029, that enables Department of Veterans Affairs medical centers nationwide to procure Arthrex's full portfolio of orthopedic surgical technologies and biologics. The ACP MAX PRP system represents specialized biologics technology for orthopedic applications, consistent with Arthrex's core focus on minimally invasive surgical instruments, implant systems, and regenerative medicine solutions serving the government healthcare system. To date, Arthrex has received over $550,000 in delivery orders under this IDC, demonstrating sustained demand for its innovative orthopedic solutions across military and veteran healthcare networks.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 6/6/25 |